XOMA Royalty Corp
XOMAAs of the close on Jul 13, 2026
Price
—
No recent closing price
Market cap
—
No recent closing price
P/E (diluted TTM)
—
No recent closing price
EPS (TTM)
—
A per-share figure for one of the last four quarters is not shown, so no four-quarter total is given
Dividend yield
—
No recent closing price
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How XOMA Royalty Corp Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated May 26, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among XOMA Royalty Corp's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-12-04 · Hughes Owen: Larger than all 9 other insider purchases of Depositary Shares - 8.375% B Cumulative Stock on file. SEC filing
- 2025-05-20 · Hughes Owen: Larger than 29 of the 30 other insider sales of Common Stock on file. SEC filing
- 2025-01-24 · BIOTECHNOLOGY VALUE FUND L P: Larger than all 9 other insider sales of Common Stock, $0.0075 par value per share on file. SEC filing
- 2024-11-13 · Hughes Owen: Larger than 28 of the 30 other insider sales of Common Stock on file. SEC filing
- 2023-09-26 · Hughes Owen: Larger than all 15 other insider purchases of Common Stock on file. SEC filing
- 2023-05-12 · Sitko Bradley: Larger than 14 of the 15 other insider purchases of Common Stock on file. SEC filing
- 2023-01-05 · BIOTECHNOLOGY VALUE FUND L P: Larger than 18 of the 19 other insider purchases of Common Stock, $0.0075 par value per share on file. SEC filing
- 2022-09-14 · BIOTECHNOLOGY VALUE FUND L P: Larger than all 19 other insider purchases of Common Stock, $0.0075 par value per share on file. SEC filing
- 2022-07-15 · Neal James R: Larger than 27 of the 30 other insider sales of Common Stock on file. SEC filing
- 2022-03-21 · Neal James R: Larger than all 30 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2025-04-03–2025-04-07: 3 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2023-09-26–2023-10-03: 4 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing )
- 2023-09-25–2023-10-02: 4 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing )
- 2023-05-16–2023-05-23: 5 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing )
- 2020-12-11–2020-12-11: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-04 | Hughes Owen · Chief Executive Officer | Depositary Shares - 8.375% B Cumulative Stock | P — Open market or private purchase | +100,000 | 25.05 | SEC filing |
| 2025-09-22 | BURNS THOMAS M. · SVP, Finance & CFO | Common Stock | S — Open market or private sale | −15 | 36.93 | SEC filing |
| 2025-09-22 | BURNS THOMAS M. · SVP, Finance & CFO | Common Stock | S — Open market or private sale | −15 | 36.81 | SEC filing |
| 2025-09-22 | BURNS THOMAS M. · SVP, Finance & CFO | Common Stock | S — Open market or private sale | −4,300 | 35.98 | SEC filing |
| 2025-06-30 | Sitko Bradley · Chief Investment Officer | Depositary Shares - 8.375% Series B Cumulative Stock | P — Open market or private purchase | +2,000 | 25.39 | SEC filing |
| 2025-05-20 | Hughes Owen · Chief Executive Officer | Common Stock | S — Open market or private sale | −25,637 | 25.38 | SEC filing |
| 2025-05-20 | BURNS THOMAS M. · SVP, Finance & CFO | Common Stock | S — Open market or private sale | −10,482 | 25.38 | SEC filing |
| 2025-05-16 | BIOTECHNOLOGY VALUE FUND L P · 10% owner | Common Stock, $0.0075 par value per share | S — Open market or private sale | −127,407 | 27.10 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-21 | Kosacz Barbara · Director | Common Stock | A — Grant, award, or other acquisition | +3,586 | SEC filing |
| 2026-05-21 | PERRY MATTHEW D · Director | Common Stock | A — Grant, award, or other acquisition | +3,586 | SEC filing |
| 2026-05-21 | Hernday Natasha · Director | Common Stock | A — Grant, award, or other acquisition | +3,586 | SEC filing |
| 2026-05-21 | LIMBER JOSEPH M · Director | Common Stock | A — Grant, award, or other acquisition | +3,586 | SEC filing |
| 2026-05-21 | Franklin Heather L · Director | Common Stock | A — Grant, award, or other acquisition | +3,586 | SEC filing |
| 2026-05-21 | WYSZOMIERSKI JACK L · Director | Common Stock | A — Grant, award, or other acquisition | +3,586 | SEC filing |
| 2026-05-14 | BIOTECHNOLOGY VALUE FUND L P · 10% owner | Common Stock, $0.0075 par value per share | C — Conversion of derivative security | +1,506,000 | SEC filing |
| 2026-05-14 | BIOTECHNOLOGY VALUE FUND L P · 10% owner | Series X Convertible Preferred Stock | C — Conversion of derivative security | −772 | SEC filing |
Showing 8 of 21 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.